Quartesian: Quartesian and ILIKOS Drug Development Solutions (ILIKOS) Announce Strategic Partnership

LIMASSOL, Cyprus, April 28, 2020 /PRNewswire/ -- Quartesian and ILIKOS jointly announce a strategic partnership aimed at:1) Establishing and executing a business development strategy bringing Quartesian's leading clinical data management, biometrics and pharmacovigilance solutions to European companies.2) Supporting ILIKOS' efforts to establish and promote clinical research platforms within Cyprus and the META (Middle-East, Turkey and Africa) regions. Quartesian is a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries. Since its inception in 2003, Quartesian has cultivated relationships with more than 200 customers, including 5 of the top 20 life science companies and 4 of the top 10 CROs."Expanding our business in Europe has been a goal for Quartesian since our formation 17 years ago. A strategic partnership with ILIKOS will enable us to grow significantly in the European market. We are also excited about supporting ILIKOS in promoting clinical research in the META regions. This is all part of our plan to offer our cost effective and efficient clinical data services to a global ...Full story available on Benzinga.com